Panel Discussion: How to Optimize Clinical Trials for Devices for Heart Failure in the Era of the Pandemic and New Medical Therapeutics

Tuesday, February 28, 2023

12:30 PM – 1:00 PM ET

Panel Moderator(s)

William T. Abraham, MD

Professor of Medicine
The Ohio State University
Columbus, Ohio, United States

Disclosure(s): Boehringer Ingelheim: Committee/Planning Member (Ongoing); Impulse Dynamics: Consultant/Advisory Board (Ongoing); V-WAVE Medical: Salary (Ongoing), Stock-privately held company (Ongoing); Zoll Respicardia: Advisor (Ongoing)
Ileana L. Pina, MD, MPH (she/her/hers)

Professor of Medicine
Thomas Jefferson University
Cleveland hts, Ohio, United States

Disclosure(s): boerhinger ingelheim: Advisory Committee/Board Member (Ongoing)
Meir Shinnar, MD, PhD

Medical Officer
FDA
Teaneck, New Jersey, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Philip Adamson, MD, MSc, FACC, FRCP (Ed)

Chief Medical Officer and Divisional Vice President
Abbott
Austin, Texas, United States

Disclosure information not submitted.
Chaim Shaul Lotan, MD

Director Heart Institute
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

No relationships to disclose
Charles A. Simonton, MD, FACC, FSCAI

EVP Chief Medical Officer
Abiomed Inc
Charlotte, North Carolina, United States

Disclosure(s): Abiomed: Employee (Ongoing)

Disclosure(s):

William T. Abraham, MD: Boehringer Ingelheim: Committee/Planning Member (Ongoing); Impulse Dynamics: Consultant/Advisory Board (Ongoing); V-WAVE Medical: Salary (Ongoing), Stock-privately held company (Ongoing); Zoll Respicardia: Advisor (Ongoing)

Ileana L. Pina, MD, MPH: boerhinger ingelheim: Advisory Committee/Board Member (Ongoing)

Meir Shinnar, MD, PhD: No financial relationships to disclose

Charles A. Simonton, MD, FACC, FSCAI: Abiomed: Employee (Ongoing)